The National Center for Tumor Diseases (NCT) Heidelberg was founded as an exceptional alliance between the German Cancer Research Center (DKFZ) and the Heidelberg University Hospital together with the Heidelberg Medical Faculty and the German Cancer Aid.
The DKFZ is Germany’s largest biomedical research center with a worldwide reputation of excellence in basic and translational cancer research. Established in 1964 as a foundation under public law, the DKFZ today has more than 3,000 employees.
To support “bench-to-bedside-and-back” translational cancer research, the National Center for Tumor Diseases (NCT) Heidelberg was founded in 2004 as one of the first Comprehensive Cancer Centers in Germany. It is a joint effort of the DKFZ and Heidelberg University Hospital together with the Heidelberg Medical Faculty and the German Cancer Aid.
As a leading center for translational cancer research, NCT Heidelberg provides an infrastructure and resources that integrate and support the entire range of DKFZ’s and the University Hospital’s clinical and translational cancer research activities as well as associated patient care. At NCT Heidelberg, patient numbers are steadily growing, and a broad spectrum of diagnostic, therapeutic, and preventive clinical trials are developed and conducted, with particular focus on academic, investigator-initiated studies.
Cancer Research UK Cambridge Centre
Our mission is to end death and disease caused by cancer through research, treatment and education.
The Cancer Research UK Cambridge Centre is a comprehensive cancer centre uniting more than 900 world-leading biologists, chemists, physicists, engineers, mathematicians, computer scientists, clinicians, nurses and allied healthcare professionals across Cambridge to tackle cancer from every angle.
Our aim is to combine world-class science with clinical expertise so that patients can benefit from the latest advances in early detection and precision treatment of cancer. We bring together researchers and clinicians from multiple departments across the University of Cambridge, Cambridge University Hospitals NHS foundation Trust, Royal Papworth Hospital NHS Foundation Trust, the Medical Research Council Laboratory of Molecular Biology, the Wellcome Genome Campus, the Babraham Research Campus, and some of the UK’s top pharmaceutical companies including AstraZeneca.
Our strategy leverages this expertise in biological, physical, computational, and clinical sciences, as well as the expertise of our national and international partners, to pursue four strategic objectives. These are impactful interdisciplinary clinical research; a proactive approach to cancer focusing on early intervention, detection and precision medicine; developing the cancer leaders of tomorrow; and partnering with the public.
Leading Cancer Centre in Europe, Gustave Roussy, is ranked among the world leaders in oncology research and patient care.
Gustave Roussy assemble the skills needed to carry out top-notch oncology research, integrating fundamental, clinical and translational research –thereby ensuring continuum between research and care inducing therapeutic advances and improvements in patient diagnosis.
With its 3100 employees, among which 520 doctors, 950 researchers and 1200 nursing staff, Gustave Roussy respond to a continuing challenge: deliver to next to 50 000 patients a year the fruits of the most recent advances. This whole community devote their energies and their skills to this great challenge: to speed up progress in order to expand the limits of knowledge and offer patients continuing improvements in the specificity of their treatment.
Gustave Roussy is always in the vanguard of progress. It brings together the best workers in fundamental, clinical and translational research. Very close collaboration between research scientists and doctors means that patients get access in the shortest possible time to the very latest developments in treatment. Through the impact of its scientific articles and the presence of its researchers at international conferences, Gustave Roussy proves the effectiveness of its model as an integrated centre for research and clinical practice. The activities of the Institute’s research units are concentrated on personalised medicine, immunotherapy, DNA repair and artificial intelligence.
Instituto Nazionale dei Tumori di Milano
The Fondazione IRCCS Istituto Nazionale dei Tumori (INT) is a foundation and government-designated centre for treatment and research (IRCCS).
The INT is a leading cancer care and research centre in Italy, exploring and developing the fields of biomedicine and public health, in order to deliver high quality healthcare services.
INT was established in 1928 and became a public IRCCS Foundation in 2006 and designated a Comprehensive Cancer Centre by the Organization of European Cancer Institute (OECI) in 2015 in recognition of its excellence both in patient care and the development of new treatments. In 2018, INT was among the best research and care institutes devoted to a single disease, and the best cancer centre based on the results and the ranking system adopted by the Italian Ministry of Health, which includes the assessment of scientific output, healthcare activity and productivity measures and networking capability. The hospital counts 482 patient beds and manages an average of 18.000 inpatients per year, for a total of 1.2 million consultations (2019). Research laboratories’ surface is roughly 3600 m2: out of the 2000 employees, 540 are devoted to research. In 2019, the overall scientific production amounted to 794 papers, 49% of which as first or last author, accounting for 5059,79 IF, upholding the positive trend of recent years. The Institute had 719 ongoing clinical trials, funded by both national and international public and private agencies.
Research at the Institute is centred around a Strategic Research Plan which identifies four main priority areas: (1) primary prevention, secondary prevention and early diagnosis ; (2) precision medicine and technological innovation (pharmacological and non-pharmacological) ; (3) complexity and rare tumours ; and (4) effectiveness studies and outcome research – offer strong guidance in the planning of current and
future initiatives. These priorities emphasize the Institute’s focus on translational research, where research activities and healthcare are linked through multidisciplinary programs designed and coordinated by scientific teams with different clinical and scientific backgrounds.
Karolinska Institutet (KI) is a comprehensive medical university covering basic, clinical, epidemiological and nursing research in virtuality all medical disciplines.
Karolinska Institutet has over 6000 full-time students in undergraduate programs, over 2000 in postdoctoral programs, and consists of 22 departments. Karolinska Institutet is localized on two campuses and collaborates with healthcare throughout the Stockholm region. Research at KI covers the entire spectrum from basic to clinical research, epidemiology and care sciences.
Overall, Karolinska Institutet has 16 programs to train medical and paramedical staff; apart from medicine and odontology, there are teaching programs in nursing, physiotherapy, biomedicine, toxicology, as well as other disciplines. The clinical part of research and training is conducted at the Karolinska University Hospital, which has two sites (the Karolinska University Hospital in Solna, and the Huddinge Hospital in Huddinge) as well as collaboration with three community hospitals. Basic research is located on both KI Campus Solna and KI Campus Flemingsberg (Huddinge). Clinical research regarding for example colorectal, breast, gynaecological and endocrine cancers as well as paediatric oncology is located at KI Campus Solna, while for example research on liver, kidney and pancreas cancers as well as research on cell therapy is conducted at KI Campus Flemingsberg. Haematology is represented at both sites. Karolinska Institutet is at the forefront of cancer research in Sweden as well as internationally. Research in this area covers all fields from molecular mechanisms and DNA repair to multidisciplinary cancer research and clinical studies. Approximately 350 research groups in 20 of the 22 departments are active in cancer research. Karolinska Institutet is together with the Karolinska University Hospital the first Comprehensive Cancer Center in Sweden accredited by the Organisation of European Cancer Institutes (OECI). Together with the umbrella organization Cancer Research KI, a strategic research area recognized by the Swedish Government, Karolinska Comprehensive Cancer Center works to improve the integration of care, research, innovation, teaching and education in cancer care.
Vall d’Hebron Institute of Oncology (VHIO)
VHIO collaborates closely with the Vall d”Hebron University Hospital’s Oncology Department, driven by a shared determination to both advance and accelerate personlized and targeted therapies against cancer.
Established in 2006, the Vall d´Hebron Institute of Oncology (VHIO) is a leading comprehensive cancer center of excellence where its cancer researchers and clinical investigators adopt a purely translational research model, working together as multidisciplinary teams. Undertaking one of Spain’s most dynamic cancer research programs, VHIO is dedicated to delivering on the promise of ‘precision’ medicine in oncology – turning cancer discovery into more effective treatments and better practice for the care of our patients.
Research at VHIO is organized across three main programs: Preclinical and Translational Research, Clinical Research, and Core Technologies. VHIO´s team of some 300 scientists and physician-scientists focus on understanding the fundamental biology of human cancer, from cellular and molecular biology and genetics to therapeutics.
VHIO’s Preclinical and Translational Research Program embraces the bench-to-bedside-and back principle -adopting a purely translational and multidisciplinary approach to research- and in parallel, develops sophisticated research tools and platforms (e.g. xenograft models to mimic patient disease and to study tumor development in optimized research models). VHIO teams strive to translate advances in molecular research to patient care as rapidly as possible, tackling the disease from all possible angles and generating synergies between molecular and clinical research in oncology, playing a key role in the drug development process.
Clinical Research at VHIO incorporates multidisciplinary cancer taskforces, and is dedicated to developing both novel agents directed to specific signaling pathways in cancer, as well as new tools to diagnose cancer earlier and better predict response to treatment. Our teams spearhead studies involving both preclinical and early-drug development, and (co) lead multiple phase I, II and III clinical trials designed to identify more effective cancer therapies tailored to individual patients. For the validation and interpretation of “omics”-based tests, VHIO’s medical oncologists and cancer biologists are provided with robust data tools to investigate biomarkers that are being developed to optimize patient stratification based on differences in response patterns to cancer therapies and treatment outcomes.
Research at VHIO is also supported and complemented by its Core Technologies: Molecular Oncology (Pathology), Cancer Genomics, and Proteomics. These units provide and develop state-of-the-art technologies and platforms for all research programs and groups at VHIO, and also function as key research groups pursuing independent research lines.
Netherlands Cancer Institute
A cure for every cancer. This is what we owe all 18 million people worldwide diagnosed with cancer each year. We are ranked among the global top 10 of cancer centers and we simply want to make the world a better and healthier place through our research and patient care.
NKI actively stimulates collaboration between clinical and basic scientists, resulting in a large translational research program.
The Netherlands Cancer Institute (NKI) has been at the international forefront of cancer care and research for more than a century. The NKI is a Comprehensive Cancer Center, officially accredited by the OECI, combining a dedicated cancer hospital (Antoni van Leeuwenhoek – AVL) and research institute (Het Nederlands Kanker Instituut – NKI) under one roof in an independent organization with one Board of Directors.
Combining health care and scientific research within the same institute offers a great, unique benefit for cancer patients. Specialized cancer care professionals work together daily in multidisciplinary teams to set up and carry out treatment plans tailored to the needs of individual patients, because no two tumors are alike. Cancer patients or patients referred for cancer diagnosis can come to our hospital, known as the Antoni van Leeuwenhoek, to make use of this personalised approach and the state-of-the-art research and treatment facilities.
The hospital has 180 beds, an outpatient clinic and a large radiotherapy department. Facilities for clinical research include a comprehensive patient database, a large collection of tumor samples with extensive clinical data, other biobanks, a data center for clinical studies, extensive diagnostic facilities, a pharmacy with a GMP-certified production unit for experimental drugs and biologicals, large patient cohorts, and active research groups in pharmacology, epidemiology and psychosocial oncology. The research institute has more than 650 active employees investigating many aspects of cancer development, diagnosis, treatment and epidemiology. Scientists at the Netherlands Cancer Institute have access to state-of-the-art research facilities supporting their basic, clinical and translational research.
Are you interested in collaborating with us, or do you wish to get more involved in our activities?
Contact us, and we will get back to you: firstname.lastname@example.org